Table 1 Scan protocols of studies.
From: A preclinical CT and MRI Liver Imaging Dataset with Anatomical, Functional and Segmentation Data
Study | Scan protocol(s) | Study mice and number of scans (per protocol) |
|---|---|---|
Hepatocellular carcinoma MRI | - anatomical T2-weighted spin echo (RARE) - diffusion-weighted imaging (EPI) | N = 7 WT HCC, control antibody IgG1 N = 7 WT HCC, control combination antibodies IgG1 + IgG2b 51 scans |
Multiparametric Liver MRI | - anatomical T1-weighted gradient echo (FcFLASH) - anatomical T2-weighted spin echo (RARE) - apparent diffusion coefficient mapping (EPI) MR1 - T1-weighted gradient echo (w/o fat suppression, (FcFLASH)) - T1 relaxometry (pre and post gadoxetic acid (RARE VTR)) - dynamic contrast enhanced MRI (FLASH) - repetition of anatomical T1-weighted gradient echo (post gadoxetic acid (FcFLASH)) MRI2 - T2 relaxometry (pre and post ferucarbotran (MSME)) - dynamic susceptibility contrast MRI (EPI) - repetition of anatomical T2-weighted spin echo (post ferucarbotran (RARE)) | N = 7 C57BL/6 J + HFD N = 10 C57BL/6 J + CCl4 N = 7 C57BL/6 J 123 scans |
Beta-glucans liver CT | - Ultra-focus fast scan mode | N = 3 C57BL/6J N = 3 C57BL/6 J + ß-gluc N = 6 C57BL/6 J + HFD N = 6 C57BL/6 J + HFD & ß-gluc 18 scans |
ICAM-1 CT fat segmentations | - Ultra-focus fast scan mode | N = 3 C57BL/6 J + HFD N = 4 C57BL/6 J ICAM-1-KO + HFD 7 scans |
CT-MRI whole body | - Total body normal scan mode - Dixon-based T2-weighted fat-water-separated turbo RARE (rapid acquisition with relaxation enhancement) | N = 12 Crl:SKH1-Hrhr mice 23 scans |
